ClinicalTrials.gg
CompletedNCT01010061Updated Sep 14, 2018Results posted

CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)

A Phase 3 interventional study of obinutuzumab and rituximab in Lymphocytic Leukemia, Chronic, sponsored by Hoffmann-La Roche. Completed at 262 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-14.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
787
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell — 16 open to participants now, 28 under way, 6 of them phase 3. obinutuzumab · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
4th of 53
787 · median 72
Started
2009
with 2 others
Phase 3
13 of 53
4 open now
Registered
1st of 53
by date
Lead sponsor
6 of 53
Hoffmann-La Roche

Among the 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 4th largest by enrollment, is one of 3 that started in 2009, is one of 13 in phase 3, and was the 1st registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

16 of the 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About obinutuzumab

obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This open-label, randomized, 3-arm study will evaluate the efficacy and safety of obinutuzumab (RO5072759) in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil alone in patients with previously untreated chronic lymphocytic leukemia (CLL). Patients will be randomized 2:2:1 to receive a maximum of six 28-day cycles of either RO5072759 (1000 mg intravenous (iv) infusion, on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2-6) plus chlorambucil (0.5 mg/kg orally, days 1 and 15 of cycles 1-6), or rituximab (iv infusion day 1, 375 mg/m\^2 cycle 1, 500 mg/m\^2 cycles 2-6) plus chlorambucil, or chlorambucil alone. Anticipated time on study treatment is >6 months and follow-up for disease-progression and safety will be at least 5 years. In the US, this trial is sponsored/managed by Genentech.

Read the detailed description

Protocol BO21004 is divided into 3 separate Unique Protocol IDs for reporting results on clinicaltrials.gov because there are 3 separate primary analyses conducted at different time-points.

  • BO21004 (Stage 1a) [NCT01010061] includes the analysis of 2 of the 3 arms obinutuzumab plus chlorambucil (Glb) compared to chlorambucil (Clb) reported here.
  • BO21004 (Stage 1b) [NCT01998880] includes the analysis of 2 of the 3 arms rituximab plus chlorambucil (RClb) compared to chlorambucil (Clb) reported separately.
  • BO21004 (Stage 2) [NCT02053610] includes the analysis of 2 of the 3 arms obinutuzumab plus chlorambucil (Glb) compared to rituximab plus chlorambucil (RClb) reported separately.
03

Conditions studied

  • Lymphocytic Leukemia, Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults >/=18 years
  • Documented Cluster of Differentiation Antigen 20 (CD20) + B-Cell Chronic Lymphocytic Lymphoma (B-CLL)
  • Previously untreated Chronic Lymphocytic Leukemia (CLL) requiring treatment according to the National Cancer Institute (NCI) criteria
  • Total Cumulative Illness Rating Scale (CIRS) > 6 and/or \< 70 ml/min

Exclusion criteria

Exclusion Criteria:

  • Prior CLL therapy
  • Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
  • History of other unless the malignancy has been in remission without treatment for >/=2 years prior to enrolment, and except for carcinoma in situ of the cervix, basal or squamous cell skin cancer, surgically treated low-grade prostate cancer, or ductal carcinoma in situ (DCIS) of the breast treated with lymphectomy alone
  • Positive hepatitis serology (, ) or positive or Human T Cell Leukemia Virus (HTLV) testing
  • Patients with active infection requiring systemic treatment
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
787 participants (actual)

Study arms

  • Experimental
    obinutuzumab + chlorambucil (GClb)

    Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).

    Drug: obinutuzumab · Drug: chlorambucil

  • Active comparator
    rituximab + chlorambucil (RClb)

    Participants received 375 mg/m\^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).

    Drug: rituximab · Drug: chlorambucil

  • Active comparator
    Chlorambucil (Clb)

    Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.

    Drug: chlorambucil

Interventions

  • 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).

    Also known as: RO5072759, GA101, GAZYVA®

  • 375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.

    Also known as: Rituxan®, MabThera®

  • Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    PFS was defined as the time from randomization to the first occurrence of progression, relapse, or death from any cause as assessed by the investigator. Progressive disease (PD) required at least one of the following: ≥50% increase in the absolute number of lymphocytes, appearance of new palpable lymph nodes (\>15 mm in longest diameter) or any new extra nodal lesion, ≥50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, ≥50% increase in the enlargement of the liver and/or spleen, Transformation to a more aggressive histology or After treatment, the progression of any cytopenia (a decrease of hemoglobin levels \>20 g/L or \<10 g/dL or a decrease of platelet counts \>50% or \<100 x 10\^9/L or by a decrease of neutrophil counts \>50% or \<1.0 x 10\^9/L).

    Time frame: Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)

  2. Percentage of Participants With Progression Free Survival Events

    Percentage of Participants with Progression Free Survival Events: disease progression, relapse, or death.

    Time frame: Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)

Secondary outcomes

  1. Progression Free Survival Based on Independent Review Committee (IRC) Data

    PFS was defined as the time from randomization to the first occurrence of progression, relapse, or death from any cause as assessed by Independent Review Committee. Progressive disease required at least one of the following: ≥50% increase in the absolute number of lymphocytes, appearance of new palpable lymph nodes (\>15 mm in longest diameter) or any new extra nodal lesion, ≥50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, ≥50% increase in the enlargement of the liver and/or spleen, Transformation to a more aggressive histology or After treatment, the progression of any cytopenia (a decrease of hemoglobin levels \>20 g/L or \<10 g/dL or a decrease of platelet counts \>50% or \<100 x 10\^9/L or by a decrease of neutrophil counts \>50% or \<1.0 x 10\^9/L).

    Time frame: Randomization to clinical cutoff date of 9 May 2013 (median observation 22.8 months)

  2. Percentage of Participants With Progression Free Survival Events Based on Independent Review Committee (IRC) Data

    Percentage of Participants with Progression Free Survival Events: progression, relapse, or death from any cause as assessed by an Independent Review Committee.

    Time frame: Randomization to clinical cutoff date of 9 May 2013 (median observation 22.8 months)

  3. Percentage of Participants With End of Treatment Response (EOTR)

    EOTR was the first response assessment 56 days from the last dose according to the International Workshop on Chronic Lymphocytic Leukaemia (IWCLL) guidelines. CR required: Peripheral blood lymphocytes below 4 x 10\^9/L, Absence of significant lymphadenopathy, No hepatomegaly, No splenomegaly, Absence of disease, Blood counts above the following values (Neutrophils \>1.5 x 10\^9/L, Platelets \>100 x 10\^9/L, Hemoglobin \>11g/dL) and Bone marrow at least normocellular for age. CRi was CR with incomplete bone marrow recovery. PR required the following for at least 2 months from end of treatment: ≥50% decrease in peripheral blood lymphocyte count from the pre-treatment value AND Either a ≥ 50% reduction in lymphadenopathy OR ≥50% reduction of liver enlargement OR ≥50% reduction of spleen enlargement PLUS at least one of the following: Neutrophils \>1.5 x 10\^9/ or ≥50% increase, Platelets \>100 x 10\^9/L or ≥50% increase, Hemoglobin 11 g/dL or ≥50% increase.

    Time frame: Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)

  4. Percentage of Participants With Best Overall Response

    Best overall response according to IWCLL guidelines was defined as the percentage of patients with CR, CRi,PR or nPR. CR required all of the following: Peripheral blood lymphocytes below 4 x 10\^9/L, Absence of significant lymphadenopathy, No hepatomegaly, No splenomegaly, Absence of disease, Blood counts above the following values (Neutrophils \>1.5 x 10\^9/L, Platelets \>100 x 10\^9/L, Hemoglobin \>11g/dL) and Bone marrow at least normocellular for age. CRi was CR with incomplete bone marrow recovery. PR required the following for at least 2 months from end of treatment: ≥50% decrease in peripheral blood lymphocyte count from the pre-treatment value AND Either a ≥ 50% reduction in lymphadenopathy OR ≥50% reduction of liver enlargement OR ≥50% reduction of spleen enlargement PLUS at least one of the following: Neutrophils \>1.5 x 10\^9/ or ≥50% increase, Platelets \>100 x 10\^9/L or ≥50% increase, Hemoglobin 11 g/dL or ≥50% increase.

    Time frame: Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)

  5. Event Free Survival

    Event-free survival (EFS) was defined as the time between date of randomization and the date of disease progression/relapse, death, or start of a new anti-leukemic therapy. Progressive disease as per IWCLL criteria required at least one of the following: ≥50% increase in the absolute number of lymphocytes, appearance of new palpable lymph nodes (\>15 mm in longest diameter) or any new extra nodal lesion, ≥50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, ≥50% increase in the enlargement of the liver and/or spleen, Transformation to a more aggressive histology or After treatment, the progression of any cytopenia (a decrease of hemoglobin levels \>20 g/L or \<10 g/dL or a decrease of platelet counts \>50% or \<100 x 10\^9/L or by a decrease of neutrophil counts \>50% or \<1.0 x 10\^9/L).

    Time frame: Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)

  6. Overall Survival

    Overall Survival (OS) was defined as the time between the date of randomization and the date of death due to any cause.

    Time frame: Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)

  7. Duration of Response

    Duration of Response was defined as the date the response \[either Complete Response (CR) or Partial Response (PR)\] was first recorded until the date of Disease Progression or death due to any cause. Response was assessed according IWCLL guidelines.

    Time frame: Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)

  8. Percentage of Participants With Molecular Remission at the End of Treatment

    Molecular remission was defined as a minimal residual disease (MRD)-negative result at the end of treatment (assessment that occurred between 56 days and 6 months of last treatment). Molecular remission was assessed for all patients using a blood sample. Additionally, a bone marrow sample was obtained from patients whom the investigator assumed to have a complete response, consistent with the IWCLL guidelines. A combined analysis of blood and bone marrow results was conducted. A patient was considered MRD negative if result was less than 1 chronic lymphocytic leukemia (CLL) cell in 10000 leukocytes (MRD value \< 0.0001) based on the method of allele specific polymerase chain reaction (ASO-PCR).

    Time frame: Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)

  9. Time to Re-Treatment/New-antileukemic Therapy

    Time to re-treatment/new anti-leukemic therapy was defined as time between the date of randomization and the date of first intake of re-treatment or new anti-leukemic therapy.

    Time frame: Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)

  10. Pharmacokinetics of Obinutuzumab (RO5072759) in Combination With Chlorambucil (Clb)

    Blood samples were collected from all patients allocated to the GClb treatment arm pre- and post-dose Day 1 of Cycles 1 to 6 and were sent to a laboratory. The concentration of obinutzumab in serum was determined using a validated enzyme-linked immunosorbent assay (ELISA) and was reported in micrograms/milliliter (μg/mL).

    Time frame: Pre- and post-dose sampling on day 1 of cycles 1-6 (Up to 26.8 months)

  11. European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 Questionnaire Score

    The EORTC Quality of Life Questionnaire QLQ-C30 was used to assess patient-reported outcomes (PRO) and symptom burden. The QLQ-C30 contains 30 items including the functional scales of physical functioning (5 items), role functioning (2 items), emotional functioning (4 items), cognitive functioning (2 items), social functioning (2 items) and symptom scales including fatigue (3 items), nausea and vomiting (2 items), and pain (4 items) and six single item scales on dyspnea, sleep disturbance, appetite loss, constipation, diarrhea and financial impact. Final scores are transformed such that they range from 0 - 100, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be of minimally important difference to participants. A positive change from Baseline indicated improvement.

    Time frame: Baseline and Cycle 4 Day 1 (Cy4D1)

  12. European Organization for Research and Treatment of Cancer (EORTC) QLQ-CLL16 Questionnaire Score

    EORTC Quality of Life Questionnaire (QLQ-CLL16) module was used to assess patient-reported outcomes and symptom burden. The QLQ-CLL16 module includes three multi-item scales assessing fatigue (2 items), treatment side effects and disease symptoms (8 items), infection (4 items) and two single item scales on social activities and future health worries. Final scores are transformed such that they range from 0 - 100, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be of minimally important difference to participants. A positive change from Baseline indicated improvement.

    Time frame: Baseline and Cycle 4 Day 1 (Cy4D1)

07

Results

Posted Apr 1, 2014

Participant flow

787 patients were enrolled in the study. Following a 6 patient safety run-in prior to randomization, 781 patients were randomized.

Participant flow — Overall Study
MilestoneObinutuzumab + Chlorambucil (GClb)Chlorambucil (Clb)
Started238118
Received study drug236116
Completed19078
Not completed4840
Withdrew: Adverse events or intercurrent illness3316
Withdrew: Disease progression28
Withdrew: Withdrew consent51
Withdrew: Death36
Withdrew: Administrative/other01
Withdrew: Refused treatment/did not cooperate20
Withdrew: Insufficient therapeutic response15
Withdrew: Violation of selection criteria01
Withdrew: Did not receive treatment22

Outcome measures

PrimaryProgression-free Survival (PFS)

PFS was defined as the time from randomization to the first occurrence of progression, relapse, or death from any cause as assessed by the investigator. Progressive disease (PD) required at least one of the following: ≥50% increase in the absolute number of lymphocytes, appearance of new palpable lymph nodes (\>15 mm in longest diameter) or any new extra nodal lesion, ≥50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, ≥50% increase in the enlargement of the liver and/or spleen, Transformation to a more aggressive histology or After treatment, the progression of any cytopenia (a decrease of hemoglobin levels \>20 g/L or \<10 g/dL or a decrease of platelet counts \>50% or \<100 x 10\^9/L or by a decrease of neutrophil counts \>50% or \<1.0 x 10\^9/L).

Time frame:
Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsObinutuzumab + Chlorambucil (GClb)Chlorambucil (Clb)
Progression-free Survival (PFS)31.1 (26.5 to 35.6)11.1 (10.7 to 11.3)
Statistical analysis
  • Obinutuzumab + Chlorambucil (GClb) vs Chlorambucil (Clb) · Log Rank, Stratified · p = <0.0001 (Type I error controlled through closed test procedure.) · Hazard ratio (hr): 0.21 · 95% CI 0.16 to 0.28Stratified by Binet stage at Baseline.
PrimaryPercentage of Participants With Progression Free Survival Events

Percentage of Participants with Progression Free Survival Events: disease progression, relapse, or death.

Time frame:
Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Reported as:
Number · Percentage of participants
Percentage of Participants With Progression Free Survival Events
Percentage of participantsObinutuzumab + Chlorambucil (GClb)Chlorambucil (Clb)
Percentage of Participants With Progression Free Survival Events72.790.7
SecondaryProgression Free Survival Based on Independent Review Committee (IRC) Data

PFS was defined as the time from randomization to the first occurrence of progression, relapse, or death from any cause as assessed by Independent Review Committee. Progressive disease required at least one of the following: ≥50% increase in the absolute number of lymphocytes, appearance of new palpable lymph nodes (\>15 mm in longest diameter) or any new extra nodal lesion, ≥50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, ≥50% increase in the enlargement of the liver and/or spleen, Transformation to a more aggressive histology or After treatment, the progression of any cytopenia (a decrease of hemoglobin levels \>20 g/L or \<10 g/dL or a decrease of platelet counts \>50% or \<100 x 10\^9/L or by a decrease of neutrophil counts \>50% or \<1.0 x 10\^9/L).

Time frame:
Randomization to clinical cutoff date of 9 May 2013 (median observation 22.8 months)
Reported as:
Median · Months
Progression Free Survival Based on Independent Review Committee (IRC) Data
MonthsObinutuzumab + Chlorambucil (GClb)Chlorambucil (Clb)
Progression Free Survival Based on Independent Review Committee (IRC) Data27.2 (23.5 to 33.0)11.2 (11.0 to 12.1)
Statistical analysis
  • Obinutuzumab + Chlorambucil (GClb) vs Chlorambucil (Clb) · Log Rank, Stratified · p = <0.0001 · Hazard ratio (hr): 0.19 · 95% CI 0.14 to 0.27Stratified by Binet stage at Baseline.
SecondaryPercentage of Participants With Progression Free Survival Events Based on Independent Review Committee (IRC) Data

Percentage of Participants with Progression Free Survival Events: progression, relapse, or death from any cause as assessed by an Independent Review Committee.

Time frame:
Randomization to clinical cutoff date of 9 May 2013 (median observation 22.8 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Progression Free Survival Events Based on Independent Review Committee (IRC) Data
Percentage of participantsObinutuzumab + Chlorambucil (GClb)Chlorambucil (Clb)
Percentage of Participants With Progression Free Survival Events Based on Independent Review Committee (IRC) Data37.476.3
SecondaryPercentage of Participants With End of Treatment Response (EOTR)

EOTR was the first response assessment 56 days from the last dose according to the International Workshop on Chronic Lymphocytic Leukaemia (IWCLL) guidelines. CR required: Peripheral blood lymphocytes below 4 x 10\^9/L, Absence of significant lymphadenopathy, No hepatomegaly, No splenomegaly, Absence of disease, Blood counts above the following values (Neutrophils \>1.5 x 10\^9/L, Platelets \>100 x 10\^9/L, Hemoglobin \>11g/dL) and Bone marrow at least normocellular for age. CRi was CR with incomplete bone marrow recovery. PR required the following for at least 2 months from end of treatment: ≥50% decrease in peripheral blood lymphocyte count from the pre-treatment value AND Either a ≥ 50% reduction in lymphadenopathy OR ≥50% reduction of liver enlargement OR ≥50% reduction of spleen enlargement PLUS at least one of the following: Neutrophils \>1.5 x 10\^9/ or ≥50% increase, Platelets \>100 x 10\^9/L or ≥50% increase, Hemoglobin 11 g/dL or ≥50% increase.

Time frame:
Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Reported as:
Number · Percentage of participants
Percentage of Participants With End of Treatment Response (EOTR)
Percentage of participantsObinutuzumab + Chlorambucil (GClb)Chlorambucil (Clb)
Complete Response (CR)17.2 (12.7 to 22.6)0.0 (0.0 to 3.1)
Complete Response incomplete (CRi)4.2 (2 to 7.6)0.0 (0.0 to 3.1)
Partial Response (PR)48.3 (41.8 to 54.9)28.8 (20.8 to 37.9)
Nodular Partial Response (nPR)7.6 (4.5 to 11.7)2.5 (0.5 to 7.3)
Stable Disease5 (2.6 to 8.6)22.9 (15.7 to 31.5)
Progressive Disease4.2 (2.0 to 7.6)28.8 (20.8 to 37.9)
No Response Assessment13.4 (NA to NA)16.9 (NA to NA)
SecondaryPercentage of Participants With Best Overall Response

Best overall response according to IWCLL guidelines was defined as the percentage of patients with CR, CRi,PR or nPR. CR required all of the following: Peripheral blood lymphocytes below 4 x 10\^9/L, Absence of significant lymphadenopathy, No hepatomegaly, No splenomegaly, Absence of disease, Blood counts above the following values (Neutrophils \>1.5 x 10\^9/L, Platelets \>100 x 10\^9/L, Hemoglobin \>11g/dL) and Bone marrow at least normocellular for age. CRi was CR with incomplete bone marrow recovery. PR required the following for at least 2 months from end of treatment: ≥50% decrease in peripheral blood lymphocyte count from the pre-treatment value AND Either a ≥ 50% reduction in lymphadenopathy OR ≥50% reduction of liver enlargement OR ≥50% reduction of spleen enlargement PLUS at least one of the following: Neutrophils \>1.5 x 10\^9/ or ≥50% increase, Platelets \>100 x 10\^9/L or ≥50% increase, Hemoglobin 11 g/dL or ≥50% increase.

Time frame:
Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Reported as:
Number · Percentage of participants
Percentage of Participants With Best Overall Response
Percentage of participantsObinutuzumab + Chlorambucil (GClb)Chlorambucil (Clb)
Complete Response (CR)26.5 (21.0 to 32.6)0.0 (0 to 3.1)
Complete Response incomplete (CRi)2.5 (0.9 to 5.4)1.7 (0.2 to 6)
Partial Response (PR)47.1 (40.6 to 53.6)31.4 (23.1 to 40.5)
Nodular Partial Response (nPR)2.1 (0.7 to 4.8)0 (0 to 3.1)
Stable Disease4.2 (2 to 7.6)21.2 (14.2 to 29.7)
Progressive Disease4.2 (2.0 to 7.6)28.8 (20.8 to 37.9)
No Response Assessment13.4 (NA to NA)16.9 (NA to NA)
Statistical analysis
  • Obinutuzumab + Chlorambucil (GClb) vs Chlorambucil (Clb) · Chi-squared · p = < 0.0001 · Difference in response rates: 45.1 · 95% CI 34.7 to 55.5
SecondaryEvent Free Survival

Event-free survival (EFS) was defined as the time between date of randomization and the date of disease progression/relapse, death, or start of a new anti-leukemic therapy. Progressive disease as per IWCLL criteria required at least one of the following: ≥50% increase in the absolute number of lymphocytes, appearance of new palpable lymph nodes (\>15 mm in longest diameter) or any new extra nodal lesion, ≥50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, ≥50% increase in the enlargement of the liver and/or spleen, Transformation to a more aggressive histology or After treatment, the progression of any cytopenia (a decrease of hemoglobin levels \>20 g/L or \<10 g/dL or a decrease of platelet counts \>50% or \<100 x 10\^9/L or by a decrease of neutrophil counts \>50% or \<1.0 x 10\^9/L).

Time frame:
Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Reported as:
Median · Months
Event Free Survival
MonthsObinutuzumab + Chlorambucil (GClb)Chlorambucil (Clb)
Event Free Survival28.7 (23.9 to 32.9)10.8 (8.0 to 11.1)
Statistical analysis
  • Obinutuzumab + Chlorambucil (GClb) vs Chlorambucil (Clb) · Log Rank, Stratified · p = <0.0001 · Hazard ratio (hr): 0.19 · 95% CI 0.15 to 0.26Stratified by Binet stage at Baseline.
SecondaryOverall Survival

Overall Survival (OS) was defined as the time between the date of randomization and the date of death due to any cause.

Time frame:
Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Reported as:
Median · Months
Overall Survival
MonthsObinutuzumab + Chlorambucil (GClb)Chlorambucil (Clb)
Overall SurvivalNA (74.2 to NA)66.7 (50.9 to NA)
Statistical analysis
  • Obinutuzumab + Chlorambucil (GClb) vs Chlorambucil (Clb) · Log Rank, Stratified · p = 0.0196 · Hazard ratio (hr): 0.68 · 95% CI 0.49 to 0.94
SecondaryDuration of Response

Duration of Response was defined as the date the response \[either Complete Response (CR) or Partial Response (PR)\] was first recorded until the date of Disease Progression or death due to any cause. Response was assessed according IWCLL guidelines.

Time frame:
Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Reported as:
Median · Months
Duration of Response
MonthsObinutuzumab + Chlorambucil (GClb)Chlorambucil (Clb)
Duration of Response24.8 (22.1 to 33.5)5.1 (3.3 to 6.7)
Statistical analysis
  • Obinutuzumab + Chlorambucil (GClb) vs Chlorambucil (Clb) · Log Rank, Stratified · p = <0.0001 · Hazard ratio (stratified): 0.19 · 95% CI 0.13 to 0.28Stratified by Binet stage at Baseline.
SecondaryPercentage of Participants With Molecular Remission at the End of Treatment

Molecular remission was defined as a minimal residual disease (MRD)-negative result at the end of treatment (assessment that occurred between 56 days and 6 months of last treatment). Molecular remission was assessed for all patients using a blood sample. Additionally, a bone marrow sample was obtained from patients whom the investigator assumed to have a complete response, consistent with the IWCLL guidelines. A combined analysis of blood and bone marrow results was conducted. A patient was considered MRD negative if result was less than 1 chronic lymphocytic leukemia (CLL) cell in 10000 leukocytes (MRD value \< 0.0001) based on the method of allele specific polymerase chain reaction (ASO-PCR).

Time frame:
Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Reported as:
Number · Percentage of participants
Percentage of Participants With Molecular Remission at the End of Treatment
Percentage of participantsObinutuzumab + Chlorambucil (GClb)Chlorambucil (Clb)
Percentage of Participants With Molecular Remission at the End of Treatment25 (18.9 to 32.6)0 (0.0 to 4.0)
SecondaryTime to Re-Treatment/New-antileukemic Therapy

Time to re-treatment/new anti-leukemic therapy was defined as time between the date of randomization and the date of first intake of re-treatment or new anti-leukemic therapy.

Time frame:
Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Reported as:
Median · Months
Time to Re-Treatment/New-antileukemic Therapy
MonthsObinutuzumab + Chlorambucil (GClb)Chlorambucil (Clb)
Time to Re-Treatment/New-antileukemic Therapy55.7 (47.4 to NA)15.1 (11.7 to 18.0)
Statistical analysis
  • Obinutuzumab + Chlorambucil (GClb) vs Chlorambucil (Clb) · Log Rank, Stratified · p = <0.0001 · Hazard ratio (stratified): 0.25 · 95% CI 0.19 to 0.35Stratified by Binet stage at Baseline.
SecondaryPharmacokinetics of Obinutuzumab (RO5072759) in Combination With Chlorambucil (Clb)

Blood samples were collected from all patients allocated to the GClb treatment arm pre- and post-dose Day 1 of Cycles 1 to 6 and were sent to a laboratory. The concentration of obinutzumab in serum was determined using a validated enzyme-linked immunosorbent assay (ELISA) and was reported in micrograms/milliliter (μg/mL).

Time frame:
Pre- and post-dose sampling on day 1 of cycles 1-6 (Up to 26.8 months)
Reported as:
Geometric mean · μg/mL
Pharmacokinetics of Obinutuzumab (RO5072759) in Combination With Chlorambucil (Clb)
μg/mLObinutuzumab + Chlorambucil (GClb)
Post-dose Cycle 1 (n=201)247 ± 41.6
Pre-dose Cycle 2 (n=198)227 ± 57.9
Post-dose Cycle 2 (n=197)587 ± 36.5
Pre-dose Cycle 3 (n=193)165 ± 68.7
Post-dose Cycle 3 (n=192)527 ± 39.7
Pre-dose Cycle 4 (n=191)156 ± 74.3
Post-dose Cycle 4 (n=189)535 ± 41.0
Pre-dose Cycle 5 (n=185)163 ± 72.4
Post-dose Cycle 5 (n=181)534 ± 39.1
Pre-dose Cycle 6 (n=185)181 ± 69.0
Post-dose Cycle 6 (n=183)525 ± 39.6
SecondaryEuropean Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 Questionnaire Score

The EORTC Quality of Life Questionnaire QLQ-C30 was used to assess patient-reported outcomes (PRO) and symptom burden. The QLQ-C30 contains 30 items including the functional scales of physical functioning (5 items), role functioning (2 items), emotional functioning (4 items), cognitive functioning (2 items), social functioning (2 items) and symptom scales including fatigue (3 items), nausea and vomiting (2 items), and pain (4 items) and six single item scales on dyspnea, sleep disturbance, appetite loss, constipation, diarrhea and financial impact. Final scores are transformed such that they range from 0 - 100, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be of minimally important difference to participants. A positive change from Baseline indicated improvement.

Time frame:
Baseline and Cycle 4 Day 1 (Cy4D1)
Reported as:
Mean · unit on a scale
European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 Questionnaire Score
unit on a scaleObinutuzumab + Chlorambucil (GClb)Chlorambucil (Clb)
Appetite Loss Scale: Baseline (n=226, 111)18.1 ± 28.4619.8 ± 29.26
Appetite Loss Scale: Cy4D1 (n=189, 92)10.2 ± 21.7714.5 ± 24.36
Cognitive Functioning Scale: Baseline (n=227, 111)80.6 ± 21.3581.8 ± 22.76
Cognitive Functioning Scale:Cy4D1 (n=190,93)83.9 ± 20.3185.8 ± 18.54
Constipation Scale: Baseline (n=225, 111)14.8 ± 23.9416.8 ± 26.92
Constipation Scale: Cy4D1 (n=188, 93)15.1 ± 25.1612.5 ± 23.53
Diarrhoea Scale: Baseline (n=226, 110)9.3 ± 20.058.8 ± 18.98
Diarrhoea Scale: Cy4D1 (n=189, 93)9.3 ± 19.476.5 ± 14.95
Dyspnoea Scale: Baseline (n=225, 109)27.1 ± 29.8923.9 ± 27.63
Dyspnoea: Cy4D1 (n=189, 91)15.9 ± 23.7122.3 ± 26.78
Emotional Functioning Scale: Baseline (n=226, 111)73.8 ± 23.4572.9 ± 25.7
Emotional Functioning Scale: Cy4D1(n=190,93)82.5 ± 18.6280.6 ± 18.48
Fatigue Scale: Baseline (n=226, 111)38 ± 25.7236.9 ± 27.01
Fatigue Scale: Cy4D1(n=189, 93)29.2 ± 20.3930.8 ± 23.00
Financial Difficulties Scale: Baseline (n=224,110)8.9 ± 20.6913.6 ± 25.26
Financial Difficulty Scale: Cy4D1(n=189,93)7.4 ± 17.649.3 ± 19.88
Nausea, Vomiting Scale: Baseline (n=227, 111)5 ± 11.187.4 ± 18.49
Nausea, Vomiting Scale: Cy4D1 (n=189,93)5.5 ± 11.517.5 ± 17.81
Pain scale: Baseline (n=228, 111)22.9 ± 27.5721.5 ± 25.66
Pain scale: Cy4D1 (n=190, 93)17.9 ± 24.0917.7 ± 25.98
Physical Functioning Scale: Baseline (n=228, 111)73.7 ± 19.8677.3 ± 18.87
Physical Functioning Scale: Cy4D1(n=189,93)78.6 ± 18.7180.9 ± 16.24
Global Health Status Scale: Baseline (n=226, 111)58.4 ± 22.857.4 ± 22.9
Global Health Status Scale: Cy4D1(n=189,93)66.7 ± 20.0363.4 ± 20.56
Role Functioning Scale: Baseline(n=227,110)76.1 ± 26.1874.7 ± 28.35
Role Functioning Scale: Cy4D1(n=189,93)79.7 ± 23.6481.5 ± 21.35
Social Functioning Scale:Baseline(n=226,110)86.3 ± 22.5283.3 ± 25.34
Social Functioning Scale: Cy4D1(n=190,93)87.8 ± 19.9785.5 ± 19.38
Insomnia Scale: Baseline (n=228,111)29.4 ± 31.1231.5 ± 32.98
Insomnia Scale: Cy4D1(n=189,93)20.6 ± 27.1324.4 ± 29.13
SecondaryEuropean Organization for Research and Treatment of Cancer (EORTC) QLQ-CLL16 Questionnaire Score

EORTC Quality of Life Questionnaire (QLQ-CLL16) module was used to assess patient-reported outcomes and symptom burden. The QLQ-CLL16 module includes three multi-item scales assessing fatigue (2 items), treatment side effects and disease symptoms (8 items), infection (4 items) and two single item scales on social activities and future health worries. Final scores are transformed such that they range from 0 - 100, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be of minimally important difference to participants. A positive change from Baseline indicated improvement.

Time frame:
Baseline and Cycle 4 Day 1 (Cy4D1)
Reported as:
Mean · unit on a scale
European Organization for Research and Treatment of Cancer (EORTC) QLQ-CLL16 Questionnaire Score
unit on a scaleObinutuzumab + Chlorambucil (GClb)Chlorambucil (Clb)
Disease Effects Scale: Baseline (n=209, 102)23 ± 18.8923.7 ± 20.18
Disease Effects Scale: Cy4D1 (n=176, 86)15.0 ± 15.1215.9 ± 14.16
Fatigue Scale: Baseline (n=209, 102)31.2 ± 25.8327.6 ± 24.65
Fatigue Scale: Cy4D1 (n=176, 86)20.9 ± 21.5123.4 ± 22.20
Future Health: Baseline (n=206, 101)47.7 ± 32.1450.8 ± 33.53
Future Health: Cy4D1 (n=175, 86)29.5 ± 31.7439.1 ± 30.33
Infection Scale: Baseline (n=209, 102)12 ± 15.9114.6 ± 17.97
Infection Scale: Cy4D1 (n=176, 86)8.9 ± 11.658.5 ± 10.70
Social Problems: Baseline (n=206, 100)24.3 ± 31.9926.3 ± 33.26
Social Problems: Cy4D1 (n=175, 85)19.4 ± 27.7522.0 ± 27.00
Treatment Side Effects Scale: Baseline (n=209,102)19.8 ± 17.717.2 ± 15.27
Treatment Side Effect Scale: Cy4D1(n=176,86)14.7 ± 14.6815.6 ± 16.11

Adverse events

Collected over Randomization to clinical cutoff (median observation 42 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Obinutuzumab + Chlorambucil (GClb)—113/241 (46.9%)215/241 (89.2%)
Chlorambucil (Clb)—45/116 (38.8%)89/116 (76.7%)
Crossover Subjects: Obinutuzumab + Chlorambucil (GClb)—8/30 (26.7%)23/30 (76.7%)
Most frequent serious events
Showing 10 of 150
Most frequent serious events
EventObinutuzumab + Chlorambucil (GClb)Chlorambucil (Clb)Crossover Subjects: Obinutuzumab + Chlorambucil (GClb)
Infusion related reactionInjury, poisoning and procedural complications27/2410/1160/30
Febrile neutropeniaBlood and lymphatic system disorders2/2415/1161/30
PneumoniaInfections and infestations10/2414/1161/30
SepsisInfections and infestations0/2414/1161/30
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)7/2410/1161/30
IleusGastrointestinal disorders0/2410/1161/30
GastroenteritisInfections and infestations0/2410/1161/30
Bowen's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2410/1161/30
Lung NeoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2410/1161/30
Metastatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2410/1161/30
Most frequent other events
Showing 10 of 20
Most frequent other events
EventObinutuzumab + Chlorambucil (GClb)Chlorambucil (Clb)Crossover Subjects: Obinutuzumab + Chlorambucil (GClb)
Infusion related reactionInjury, poisoning and procedural complications147/2410/11615/30
NeutropeniaBlood and lymphatic system disorders99/24121/11612/30
NauseaGastrointestinal disorders32/24129/1163/30
ThrombocytopeniaBlood and lymphatic system disorders36/2419/1167/30
LeukopeniaBlood and lymphatic system disorders17/2410/1165/30
CoughRespiratory, thoracic and mediastinal disorders22/2418/1164/30
VomitingGastrointestinal disorders13/24114/1160/30
DiarrhoeaGastrointestinal disorders23/24113/1163/30
AnaemiaBlood and lymphatic system disorders27/24112/1163/30
PyrexiaGeneral disorders25/2418/1162/30

Baseline characteristics

Baseline measures are based on the participants who were included in the Stage 1a analysis.

Age, Customized
Age, Customized(participants)Obinutuzumab + Chlorambucil (GClb)Chlorambucil (Clb)Total
<65 years422668
>=65 years19692288
Sex: Female, Male
Sex: Female, Male(Participants)Obinutuzumab + Chlorambucil (GClb)Chlorambucil (Clb)Total
Female9843141
Male14075215
08

Study locations

262 sites
  • San Diego, California 92123, United States
  • Chicago, Illinois 60637, United States
  • Baltimore, Maryland 21215, United States
  • Green Bay, Wisconsin 54311, United States
  • Waukesha, Wisconsin 53188, United States
  • Buenos Aires, 1406, Argentina
  • Buenos Aires, 1425, Argentina
  • Buenos Aires, C1114AAN, Argentina
  • Buenos Aires, C1180AAX, Argentina
  • Buenos Aires, C1221ADC, Argentina
  • Buenos Aires, C1431FWO, Argentina
  • Rosario, 2000, Argentina
  • Adelaide, New South Wales 5011, Australia
  • Gosford, New South Wales 2250, Australia
  • Kogarah, New South Wales 2217, Australia
  • Liverpool, New South Wales 2170, Australia
  • St. Leonards, New South Wales 2065, Australia
  • Sydney, New South Wales 2139, Australia
  • Greenslopes, Queensland 4120, Australia
  • Southport, Queensland 4215, Australia
  • Woolloongabba, Queensland 4102, Australia
  • Kurralta Park, South Australia 5037, Australia
  • Frankston, Victoria 3199, Australia
  • Melbourne, Victoria 3168, Australia
  • Graz, 8036, Austria
  • Innsbruck, 6020, Austria
  • Wien, 1090, Austria
  • Wien, 1160, Austria
  • Goiania, GO 74140-050, Brazil
  • Belo Horizonte, MG 31270-901, Brazil
  • Porto Alegre, RS 90880-480, Brazil
  • Santo Andre, SP 09060-650, Brazil
  • Sao Paulo, SP 05403-000, Brazil
  • Pleven, 5800, Bulgaria
  • Plovdiv, 4002, Bulgaria
  • Sofia, 1756, Bulgaria
  • Varna, 9010, Bulgaria
  • Vratsa, 3000, Bulgaria
  • Calgary, Alberta T2N 4N2, Canada
  • Edmonton, Alberta T6G 1Z2, Canada
  • Winnipeg, Manitoba R0C 2Z0, Canada
  • Halifax, Nova Scotia B3H 2Y9, Canada
  • Barrie, Ontario L4M 6M2, Canada
  • Ottawa, Ontario K1H 8L6, Canada
  • Montreal, Quebec H2L 4M1, Canada
  • Rimouski, Quebec G5L 5T1, Canada
  • Zagreb, 10000, Croatia
  • Brno, 625 00, Czechia
  • Hradec Kralove, 500 05, Czechia
  • Praha 2, 128 08, Czechia
  • Aalborg, 9000, Denmark
  • København, 2100, Denmark
  • Odense, 5000, Denmark
  • Vejle, 7100, Denmark
  • Århus, 8000, Denmark
  • Cairo, 11796, Egypt
  • Tallinn, 13419, Estonia
  • Tartu, 51014, Estonia
  • Angers, 49933, France
  • Bobigny, 93009, France
  • Caen, 14076, France
  • Clermont Ferrand, 63003, France
  • Creteil, 94010, France
  • Le Mans, 72015, France
  • Lille, 59037, France
  • Lyon, 69373, France
  • Marseille, 13273, France
  • Montpellier, 34295, France
  • Nantes, 44093, France
  • Paris, 75475, France
  • Paris, 75651, France
  • Pessac, 33604, France
  • Pierre Benite, 69495, France
  • Poitiers, 86021, France
  • Reims, 51092, France
  • Rennes, 35033, France
  • Rouen, 76038, France
  • Toulouse, 31059, France
  • Tours, 37044, France
  • Vandoeuvre Les Nancy, 54511, France
  • Ahaus, 48683, Germany
  • Amberg, 92224, Germany
  • Ansbach, 91522, Germany
  • Bamberg, 96049, Germany
  • Berlin, 12200, Germany
  • Bonn, 53113, Germany
  • Bremen, 28177, Germany
  • Bremen, 28209, Germany
  • Bremen, 28239, Germany
  • Delitzsch, 04509, Germany
  • Detmold, 32756, Germany
  • Dresden, 01127, Germany
  • Dresden, 01307, Germany
  • Duisburg, 47051, Germany
  • Erlangen, 91052, Germany
  • Erlangen, 91054, Germany
  • Eschweiler, 52249, Germany
  • Essen, 45122, Germany
  • Essen, 45239, Germany
  • Esslingen, 73730, Germany

Showing the first 100 of 262 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Jaramillo S, Agathangelidis A, Schneider C, Bahlo J, Robrecht S, Tausch E, Bloehdorn J, Hoechstetter M, Fischer K, Eichhorst B, Goede V, Hallek M, Dohner H, Rosenquist R, Ghia P, Stamatopoulos K, Stilgenbauer S. Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). Haematologica. 2020 Nov 1;105(11):2598-2607. doi: 10.3324/haematol.2019.231027. PubMed 33131249 ↗
  • Gibiansky E, Gibiansky L, Buchheit V, Frey N, Brewster M, Fingerle-Rowson G, Jamois C. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study. Br J Clin Pharmacol. 2019 Sep;85(9):1935-1945. doi: 10.1111/bcp.13974. Epub 2019 Jul 12. PubMed 31050355 ↗
  • Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Dohner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8. PubMed 24401022 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2009 to primary completion in Jul 2012, 30 months.

Results were first posted in Apr 2014, 1 year 9 months after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 30 months is below that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2009
First posted
Nov 9, 2009
StartActual
Dec 21, 2009
Primary completionActual
Jul 1, 2012
CompletionActual
Aug 23, 2017
Results first posted
Apr 1, 2014
Last update
Sep 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01010061
Lead sponsor
Hoffmann-La Roche
Collaborators
German CLL Study Group, Genentech, Inc.
Responsible party
Sponsor
First posted
Nov 9, 2009
Start date
Dec 21, 2009
Primary completion
Jul 1, 2012
Completion
Aug 23, 2017
Results posted
Apr 1, 2014
Last update
Sep 14, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obinutuzumab

Start the discussion